Announcements
- Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
- Fate Therapeutics to Present at Upcoming March Investor Conferences
More ▼
Key statistics
On Friday, Fate Therapeutics Inc (F6T:FRA) closed at 3.20, 103.11% above the 52 week low of 1.58 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.17 |
---|---|
High | 3.20 |
Low | 3.17 |
Bid | 3.39 |
Offer | 3.43 |
Previous close | 3.15 |
Average volume | 439.40 |
---|---|
Shares outstanding | 113.83m |
Free float | 112.03m |
P/E (TTM) | -- |
Market cap | 418.90m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of May 31 2024 10:30 BST.
More ▼